XOMA (XOMA) Revenue & Revenue Breakdown
XOMA Revenue Highlights
Latest Revenue (Y)
$4.76M
Latest Revenue (Q)
$7.20M
Main Geography (Y)
UNITED STATES
XOMA Revenue by Period
XOMA Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | -21.06% |
2022-12-31 | - | -84.21% |
2021-12-31 | - | 29.86% |
2020-12-31 | - | 59.96% |
2019-12-31 | - | 246.67% |
2018-12-31 | - | -89.94% |
2017-12-31 | - | 846.98% |
2016-12-31 | - | -89.97% |
2015-12-31 | - | 193.90% |
2014-12-31 | - | -46.78% |
2013-12-31 | - | 4.94% |
2012-12-31 | - | -41.95% |
2011-12-31 | - | 72.99% |
2010-12-31 | - | -65.82% |
2009-12-31 | - | 44.78% |
2008-12-31 | - | -19.31% |
2007-12-31 | - | 185.62% |
2006-12-31 | - | 58.01% |
2005-12-31 | - | 409.39% |
2004-12-31 | - | -84.99% |
2003-12-31 | - | -18.49% |
2002-12-31 | - | 73.33% |
2001-12-31 | - | 159.48% |
2000-12-31 | - | 177.46% |
1999-12-31 | - | -61.90% |
1998-12-31 | - | -65.76% |
1997-12-31 | - | 411.11% |
1996-12-31 | - | 200.00% |
1995-12-31 | - | -29.41% |
1994-12-31 | - | 183.33% |
1993-12-31 | - | - |
XOMA Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | -35.08% |
2024-06-30 | - | 644.03% |
2024-03-31 | - | -18.71% |
2023-12-31 | - | 120.84% |
2023-09-30 | - | -49.94% |
2023-06-30 | - | 279.41% |
2023-03-31 | - | -70.59% |
2022-12-31 | - | 229.49% |
2022-09-30 | - | -54.12% |
2022-06-30 | - | -68.36% |
2022-03-31 | - | -91.36% |
2021-12-31 | - | 3723.83% |
2021-09-30 | - | 4.33% |
2021-06-30 | - | 140.27% |
2021-03-31 | - | -98.64% |
2020-12-31 | - | 4851.53% |
2020-09-30 | - | 25.45% |
2020-06-30 | - | -44.78% |
2020-03-31 | - | 90.07% |
2019-12-31 | - | -95.22% |
2019-09-30 | - | 820.48% |
2019-06-30 | - | -88.17% |
2019-03-31 | - | 382.55% |
2018-12-31 | - | 88.06% |
2018-09-30 | - | -60.27% |
2018-06-30 | - | 387.04% |
2018-03-31 | - | -91.36% |
2017-12-31 | - | -85.19% |
2017-09-30 | - | 232.26% |
2017-06-30 | - | 4088.46% |
2017-03-31 | - | -50.38% |
2016-12-31 | - | -17.48% |
2016-09-30 | - | 43.34% |
2016-06-30 | - | -88.82% |
2016-03-31 | - | -91.78% |
2015-12-31 | - | 2223.19% |
2015-09-30 | - | -18.31% |
2015-06-30 | - | -4.22% |
2015-03-31 | - | -39.03% |
2014-12-31 | - | -15.34% |
2014-09-30 | - | -14.01% |
2014-06-30 | - | 75.16% |
2014-03-31 | - | -72.79% |
2013-12-31 | - | 98.57% |
2013-09-30 | - | -11.73% |
2013-06-30 | - | -24.35% |
2013-03-31 | - | 27.88% |
2012-12-31 | - | 1.94% |
2012-09-30 | - | -21.82% |
2012-06-30 | - | -5.98% |
2012-03-31 | - | 0.18% |
2011-12-31 | - | -39.32% |
2011-09-30 | - | -1.79% |
2011-06-30 | - | 5.96% |
2011-03-31 | - | 62.45% |
2010-12-31 | - | -11.90% |
2010-09-30 | - | 83.39% |
2010-06-30 | - | -17.50% |
2010-03-31 | - | -66.65% |
2009-12-31 | - | -21.24% |
2009-09-30 | - | 182.54% |
2009-06-30 | - | -75.55% |
2009-03-31 | - | 7.54% |
2008-12-31 | - | 367.70% |
2008-09-30 | - | -28.99% |
2008-06-30 | - | -7.80% |
2008-03-31 | - | -18.11% |
2007-12-31 | - | - |
XOMA Revenue Breakdown
XOMA Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Asia Pacific | - | - | - | - | - |
UNITED STATES | - | - | - | - | - |
United States | - | - | - | - | - |
Europe | - | - | - | - | - |
U | - | - | - | - | - |
Latest
XOMA Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
TNGX | Tango Therapeutics | - | - |
HOWL | Werewolf Therapeutics | - | - |
RVMD | Revolution Medicines, Inc. Warrant | - | - |
STOK | Stoke Therapeutics | - | - |
XOMA | XOMA | - | - |
CRNX | Crinetics Pharmaceuticals | - | - |
DSGN | Design Therapeutics | - | - |
RZLT | Rezolute | - | - |
CCCC | C4 Therapeutics | - | - |
DBTX | Decibel Therapeutics | - | - |
TALS | Tourmaline Bio | - | - |
DYN | Dyne Therapeutics | - | - |
PASG | Passage Bio | - | - |
ELYM | Eliem Therapeutics | - | - |
ACRV | Acrivon Therapeutics | - | - |
ACHL | Achilles Therapeutics | - | - |
CELC | Celcuity | - | - |
VINC | Vincerx Pharma | - | - |
THRD | Third Harmonic Bio | - | - |
EWTX | Edgewise Therapeutics | - | - |
SIOX | Sio Gene Therapies | - | - |